Technical Data
031672
AF4, NT (MLLT2, Mixed Lineage Leukemia, Translocated to, 2, ALL1 fused gene from chromosome 4, AF4, FEL)
Description:
MLLT2 is involved in acute leukemias through a chromosomal translocation t(4;11)(q21;q23) that involves mllt2 and mll/hrx. AF-4 (MLLT2), AF-9, and ENL proteins contain nuclear targeting sequences as well as serine-rich and proline-rich regions. Stretches abundant in basic amino acids are also present in the three proteins. These results suggest that the different proteins fused to ALL-1 polypeptide(s) provide similar functional domains. AF4 is a serine- and proline-rich putative transcription factor with a glutamine-rich carboxyl terminus. The composition of the complete MLL-AF4 fusion product argues that it may act through either a gain-of-function or a dominant negative mechanism in leukemogenesis.

Applications:
Suitable for use in ELISA

Recommended Dilution:
ELISA: 1:1,000

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabIgGPurified
SizeStorageShippingSourceHost
200ul-20CBlue IceHumanRabbit
Concentration:
As reported
Immunogen:
AF4 (MLLT2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human MLLT2.
Purity:
Purified by saturated ammonium sulfate precipitation followed by dialysis against PBS.
Form
Supplied as a liquid in PBS, pH 7.2, 0.09% sodium azide.
Specificity:
Human
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Bursen, A., et al., Oncogene 23(37):6237-6249 (2004).
Beausoleil, S.A., et al., Proc. Natl. Acad. Sci. U.S.A. 101(33):12130-12135 (2004).
Caslini, C., et al., Leukemia 18(6):1064-1071 (2004).
Bertrand, F.E., et al., Leukemia 17(12):2454-2459 (2003).
Reichel, M., et al., Leukemia 15(2):286-288 (2001).